{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:41:25Z","timestamp":1783579285642,"version":"3.55.0"},"reference-count":42,"publisher":"The Endocrine Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>Context:<\/jats:title>\n                  <jats:p>There are no specific biochemical bone markers available for osteogenesis imperfecta (OI), and the role of sclerostin as a key regulator of bone formation in OI is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives:<\/jats:title>\n                  <jats:p>We aimed to evaluate the role of sclerostin and its association with bone turnover markers as well as body composition parameters in adult patients with different types of OI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design, Setting, and Participants:<\/jats:title>\n                  <jats:p>This was a case-control study in 27 adult patients and 50 healthy age- and gender-matched controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures:<\/jats:title>\n                  <jats:p>Serum sclerostin levels and bone turnover markers including serum osteocalcin, amino terminal propeptide of type I procollagen, and CrossLaps as well as body composition parameters were determined in mild OI stage I (OI-I) and moderate-severe OI stages III-IV (OI-III-IV), according to Sillence classification. Data were compared with healthy controls.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Sclerostin levels were significantly lower in OI-I (19.9 \u00b1 10.9 pmol\/L; P &amp;lt; .001) and OI-III-IV (13.3 \u00b1 10.0 pmol\/L; P &amp;lt; .001) compared with healthy adults (45.3 \u00b1 14.9 pmol\/L), even after adjustment for age, sex, bone mineral content, and body mass index. CrossLaps and PTH were significantly lower in OI-I (0.197 \u00b1 0.15 ng\/L; P = .007 and 33.7 \u00b1 19.1 pg\/L; P = .033, respectively) and OI-III-IV (0.221 \u00b1 0.18 ng\/L; P = .039, and 27.9 \u00b1 14.7 pg\/L; P = .001, respectively) than in healthy controls (0.322 \u00b1 0.15 ng\/L and 45.0 \u00b1 16.6 pg\/L). Amino-terminal propeptide of type I procollagen was below the reference range for OI-I and OI-III-IV. Patients with OI were shorter and lighter and had a decreased bone mineral content (P &amp;lt; .001) but similar fat distribution and lean body mass, compared with controls. Serum sclerostin levels were not related to any bone marker except osteocalcin, the number of prevalent fractures, or body composition readings.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>Decreased sclerostin levels in OI might reflect a down-regulation or negative feedback mechanism to prevent further bone loss.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2013-2244","type":"journal-article","created":{"date-parts":[[2013,11,8]],"date-time":"2013-11-08T04:36:14Z","timestamp":1383885374000},"page":"E311-E319","source":"Crossref","is-referenced-by-count":18,"title":["Serum Sclerostin Levels Are Decreased in Adult Patients With Different Types of Osteogenesis Imperfecta"],"prefix":"10.1210","volume":"99","author":[{"given":"Roland","family":"Kocijan","sequence":"first","affiliation":[{"name":"Medical Department II (R.K., C.M., J.H., H.R.), St Vincent Hospital, The VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, 1060 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Muschitz","sequence":"additional","affiliation":[{"name":"Medical Department II (R.K., C.M., J.H., H.R.), St Vincent Hospital, The VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, 1060 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Fahrleitner-Pammer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (A.F.-P., K.A.), Division of Endocrinology and Metabolism, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Amrein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine (A.F.-P., K.A.), Division of Endocrinology and Metabolism, Medical University of Graz, 8036 Graz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Pietschmann","sequence":"additional","affiliation":[{"name":"Department of Pathophysiology and Allergy Research (P.P.), Center for Pathophysiology, Infectiology, and Immunology, Medical University of Vienna, 1090 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Haschka","sequence":"additional","affiliation":[{"name":"Medical Department II (R.K., C.M., J.H., H.R.), St Vincent Hospital, The VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, 1060 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Dinu","sequence":"additional","affiliation":[{"name":"Central Laboratory (S.D., S.K.) St. Vincent Group, 1060 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Kapiotis","sequence":"additional","affiliation":[{"name":"Central Laboratory (S.D., S.K.) St. Vincent Group, 1060 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Resch","sequence":"additional","affiliation":[{"name":"Medical Department II (R.K., C.M., J.H., H.R.), St Vincent Hospital, The VINFORCE Study Group, Academic Teaching Hospital of Medical University of Vienna, 1060 Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071613344002400_B1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","article-title":"New perspectives on osteogenesis imperfecta","volume":"7","author":"Forlino","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"2020071613344002400_B2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic heterogeneity in osteogenesis imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J Med Genet"},{"key":"2020071613344002400_B3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s00256-012-1512-4","article-title":"Femoral geometric parameters and BMD measurements by DXA in adult patients with different types of osteogenesis imperfecta","volume":"42","author":"Kocijan","journal-title":"Skeletal Radiol"},{"key":"2020071613344002400_B4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","article-title":"Sclerostin: current knowledge and future perspectives","volume":"87","author":"Moester","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"2020071613344002400_B5","doi-asserted-by":"crossref","first-page":"26770","DOI":"10.1074\/jbc.M504308200","article-title":"SOST is a ligand for LRP5\/LRP6 and a Wnt signaling inhibitor","volume":"280","author":"Semenov","year":"2005","journal-title":"J Biol Chem"},{"key":"2020071613344002400_B6","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1210\/en.2003-1492","article-title":"Spaciotemporal association and bone morphogenetic protein regulation of sclerostin and osterix expression during embryonic osteogenesis","volume":"145","author":"Ohyama","year":"2004","journal-title":"Endocrinology"},{"key":"2020071613344002400_B7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/jbmr.217","article-title":"Relation of age, gender, and bone mass to circulating sclerostin levels in women and men","volume":"26","author":"Modder","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2020071613344002400_B8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1210\/jc.2011-2152","article-title":"Sclerostin and its association with physical activity, age, gender, body composition, and bone mineral content in healthy adults","volume":"97","author":"Amrein","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344002400_B9","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1210\/jc.2010-0067","article-title":"Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss","volume":"95","author":"Gaudio","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344002400_B10","doi-asserted-by":"crossref","first-page":"E1736","DOI":"10.1210\/jc.2012-1579","article-title":"Serum sclerostin increases in healthy adult men during bed rest","volume":"97","author":"Spatz","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344002400_B11","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/jbmr.479","article-title":"Determinants of serum sclerostin in healthy pre- and postmenopausal women","volume":"26","author":"Ardawi","year":"2011","journal-title":"J Bone Miner Res"},{"key":"2020071613344002400_B12","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00198-012-1978-x","article-title":"Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study","volume":"24","author":"Garnero","year":"2013","journal-title":"Osteoporos Int"},{"issue":"4","key":"2020071613344002400_B13","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/jbmr.1823","article-title":"Lower fracture risk in older men with higher sclerostin concentration\u2014a prospective analysis from the MINOS study","volume":"28","author":"Szulc","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2020071613344002400_B14","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1210\/jc.2011-3419","article-title":"Serum sclerostin and risk of hip fracture in older Caucasian women","volume":"97","author":"Arasu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071613344002400_B15","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1002\/jbmr.1718","article-title":"High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research study","volume":"27","author":"Ardawi","year":"2012","journal-title":"J Bone Miner Res"},{"key":"2020071613344002400_B16","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2265.2011.04315.x","article-title":"Serum sclerostin levels were positively correlated with fat mass and bone mineral density in central south Chinese postmenopausal women","volume":"76","author":"Sheng","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071613344002400_B17","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071613344002400_B18","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.maturitas.2012.08.002","article-title":"New therapeutic targets for osteoporosis: beyond denosumab","volume":"73","author":"Lim","year":"2012","journal-title":"Maturitas"},{"key":"2020071613344002400_B19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin antibody improves skeletal parameters in a Brtl\/+ mouse model of osteogenesis imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J Bone Miner Res"},{"key":"2020071613344002400_B20","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00198-010-1525-6","article-title":"Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women\u2014the six-month effect of risedronate and teriparatide","volume":"23","author":"Polyzos","year":"2012","journal-title":"Osteoporos Int"},{"key":"2020071613344002400_B21","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.bone.2013.06.013","article-title":"The association between insulin-like growth factor I and bone turnover markers in the general adult population","volume":"56","author":"Niemann","year":"2013","journal-title":"Bone"},{"key":"2020071613344002400_B22","first-page":"403","article-title":"Evaluation of IDS-iSYS intact parathyroid hormone (iPTH) and comparison to Siemens Advia Centaur iPTH assay in chronic renal failure patients and in controls","volume":"58","author":"Koivula","year":"2012","journal-title":"Clin Lab"},{"key":"2020071613344002400_B23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7754\/Clin.Lab.2012.120527","article-title":"Four automated 25-OH total vitamin D immunoassays and commercial liquid chromatography tandem-mass spectrometry in Finnish population","volume":"59","author":"Koivula","year":"2013","journal-title":"Clin Lab"},{"key":"2020071613344002400_B24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1515\/CCLM.2004.017","article-title":"Performance evaluation of automated assays for \u03b2-CrossLaps, N-MID-Osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study)","volume":"42","author":"Schmidt-Gayk","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"2020071613344002400_B25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/ejcn.2010.190","article-title":"In vivo precision of the GE Lunar iDXA densitometer for the measurement of total body composition and fat distribution in adults","volume":"65","author":"Hind","year":"2011","journal-title":"Eur J Clin Nutr"},{"key":"2020071613344002400_B26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S8756-3282(00)00269-6","article-title":"Static and dynamic bone histomorphometry in children with osteogenesis imperfecta","volume":"26","author":"Rauch","year":"2000","journal-title":"Bone"},{"key":"2020071613344002400_B27","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1359\/jbmr.080804","article-title":"Cellular mechanism of decreased bone in Brtl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors","volume":"23","author":"Uveges","year":"2008","journal-title":"J Bone Miner Res"},{"key":"2020071613344002400_B28","first-page":"20","article-title":"[Bone tissue in osteogenesis imperfecta: light and electron microscopic studies]","volume":"68","author":"Osipenkova-Vichtomova","year":"2006","journal-title":"Arkhiv Patologii"},{"key":"2020071613344002400_B29","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1007\/s00198-005-1905-5","article-title":"Musculoskeletal manifestations of mild osteogenesis imperfecta in the adult","volume":"16","author":"McKiernan","year":"2005","journal-title":"Osteoporos Int"},{"key":"2020071613344002400_B30","article-title":"Functioning and quality of life in adults with mild-to-moderate osteogenesis imperfecta [published online December 27, 2012]","author":"Balkefors","journal-title":"Physiother Res Int"},{"key":"2020071613344002400_B31","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bone.2004.02.023","article-title":"Bone turnover markers in patients with osteogenesis imperfecta","volume":"34","author":"Braga","year":"2004","journal-title":"Bone"},{"key":"2020071613344002400_B32","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/GIM.0b013e3181a1ff7b","article-title":"Osteogenesis imperfecta: recent findings shed new light on this once well-understood condition","volume":"11","author":"Basel","year":"2009","journal-title":"Genet Med"},{"key":"2020071613344002400_B33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1373\/clinchem.2006.083055","article-title":"Bone formation markers in adults with mild osteogenesis imperfecta","volume":"53","author":"Cundy","year":"2007","journal-title":"Clin Chem"},{"key":"2020071613344002400_B34","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.bone.2008.11.006","article-title":"Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations","volume":"44","author":"Garnero","year":"2009","journal-title":"Bone"},{"key":"2020071613344002400_B35","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1359\/jbmr.090310","article-title":"Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis","volume":"24","author":"Delmas","year":"2009","journal-title":"J Bone Miner Res"},{"key":"2020071613344002400_B36","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMc062792","article-title":"Prolonged bisphosphonate release after treatment in children","volume":"356","author":"Papapoulos","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071613344002400_B37","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1136\/adc.86.5.356","article-title":"Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta","volume":"86","author":"Astrom","year":"2002","journal-title":"Arch Dis Child"},{"key":"2020071613344002400_B38","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","article-title":"Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists","volume":"23","author":"Bradbury","year":"2012","journal-title":"Osteoporos Int"},{"key":"2020071613344002400_B39","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00198-011-1675-1","article-title":"Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women","volume":"23","author":"Chung","year":"2012","journal-title":"Osteoporos Int"},{"key":"2020071613344002400_B40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.bone.2011.11.028","article-title":"Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin","volume":"50","author":"Gatti","year":"2012","journal-title":"Bone"},{"key":"2020071613344002400_B41","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1074\/jbc.M705092200","article-title":"Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost\/sclerostin","volume":"283","author":"Robling","year":"2008","journal-title":"J Biol Chem"},{"key":"2020071613344002400_B42","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.1592","article-title":"Bone geometry, density, and microarchitecture in the distal radius and tibia in adults with osteogenesis imperfecta type I assessed by high-resolution pQCT","volume":"27","author":"Folkestad","year":"2012","journal-title":"J Bone Miner Res"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/99\/2\/E311\/9048738\/jcemE311.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/99\/2\/E311\/9048738\/jcemE311.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T00:09:36Z","timestamp":1594944576000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/99\/2\/E311\/2537192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,1]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2013-2244","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,1]]}}}